









Markets
/
Stocks
/
nasdaq-tmci
/

Treace Medical Concepts Inc

TMCI

7.190USD

+0.150+2.13%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

453.27MMarket Cap

LossP/E TTM



Treace Medical Concepts Inc

7.190

+0.150+2.13%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

104 / 207

Overall Ranking

262 / 4721

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Buy

Current Rating

8.700

Target Price

+23.58%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Treace Medical Concepts, Inc. is a medical technology company. The Company is focused on advancing the standard of care for the surgical management of bunion and related midfoot deformities. It has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. It also has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of the midfoot as well as its Hammertoe PEEK Fixation System designed to address hammertoe, claw toe and mallet toe deformities. The Lapiplasty, Adductoplasty and Hammertoe PEEK Fixation Systems are comprised of single-use implant kits and reusable instrument trays. The Company sells these products to physicians, surgeons, hospitals and ambulatory surgery centers in the United States.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 47.60% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 30.20.

Fairly Valued

The company’s latest PE is -9.17, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 55.28M shares, decreasing 27.13% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.73M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 6.26, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 47.39M, representing a year-over-year increase of 6.60%, while its net profit experienced a year-over-year increase of 17.96%.

Score

Industry at a Glance

Previous score

6.26

Change



Financials

5.75

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.63

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.44

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.34

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.12

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 1.20, which is lower than the Healthcare Equipment & Supplies industry's average of 2.00. Its current P/E ratio is -8.98, which is -10.54% below the recent high of -8.04 and -146.91% above the recent low of -22.18.

Score

Industry at a Glance

Previous score

1.20

Change

1.6

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 104/207

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 7.00, which is lower than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Treace Medical Concepts Inc is 8.00, with a high of 12.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts

Buy

Current Rating

8.700

Target Price

+23.58%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

118

Total

Median

Average

Company name

Ratings

Analysts

Treace Medical Concepts Inc

TMCI

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

Dexcom Inc

DXCM

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 5.62, which is lower than the Healthcare Equipment & Supplies industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 7.61 and the support level at 6.63, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.62

Change

0.21

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.135

Neutral

RSI(14)

54.438

Neutral

STOCH(KDJ)(9,3,3)

35.845

Neutral

ATR(14)

0.370

High Vlolatility

CCI(14)

27.726

Neutral

Williams %R

56.410

Sell

TRIX(12,20)

0.358

Sell

StochRSI(14)

78.489

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

7.148

Buy

MA10

7.186

Buy

MA20

7.274

Sell

MA50

6.540

Buy

MA100

6.409

Buy

MA200

7.367

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 7.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 87.88%, representing a quarter-over-quarter increase of 1.62%. The largest institutional shareholder is The Vanguard, holding a total of 2.73M shares, representing 4.31% of shares outstanding, with 1.55% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Treace (John T.)

11.70M

-1.34%

Armistice Capital LLC

6.21M

+0.03%

BlackRock Institutional Trust Company, N.A.

3.40M

+0.43%

William Blair Investment Management, LLC

3.06M

+4.14%

The Vanguard Group, Inc.

Star Investors

2.71M

-1.01%

Gagnon Securities LLC

2.71M

+55.16%

Treace (James T)

1.78M

CIBC Private Wealth Management

2.29M

+21.46%

JP Morgan Asset Management

1.40M

-6.29%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 3.31, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 0.71. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.